Key Catalysts and their Impact on Pharma Markets

Intratumor heterogeneity (ITH) is a major underlying cause of therapy resistance and disease recurrence and is a read-out of how a tumor has grown. Current methods to analyze genetic ITH rely on the sequencing of ‘bulk’ or flow-sorted populations, in which the spatial context of tumor subclones is not preserved, and rare subclones may not be detected. These shortfalls can be addressed with BaseScope™ ISH–a unique mutation-specific RNA in situ hybridization assay. The BaseScope assay represents a significant technical advance for in situ mutation detection and provides new insight into the mechanisms of tumor evolution with potential ramifications for selecting patients for treatment. Join us to learn more about this new approach to ITH analysis.

Antibody Drug Conjugates (ADCs) have a highly specific mechanism of action which is an advantage for the treatment of several oncology indications. They are made of a highly toxic payload, a linker, and an antibody.

Patient Support Programs (PSPs) have changed dramatically over the past decade; they have become global activities, and grown significantly in scale and complexity. While PSPs are also an increasingly valuable resource for pharmacovigilance due to the extensive patient safety data they generate, they have suffered from the traditional lack of standardized mechanisms for recording, reconciling and managing this data, resulting in resource heavy processes, and a lost opportunity for deeper product understanding for Pharma. Fortunately, new technologies are helping to tackle this challenge.

Discovering new “drug-like” and synthetically viable compounds via artificial intelligence (AI) is of great interest to medicinal chemists.